Catalysts / APGE
Upcoming FDA decisions and readouts we track for Apogee Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Apogee Therapeutics (APGE, listed on Nasdaq). It concerns APG279 (zumilokibart + APG990) (Atopic dermatitis).
First on the list: the Phase 1B readout for APG279 (zumilokibart + APG990) (Atopic dermatitis), guided by the company to H2 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Apogee Therapeutics APGE · Nasdaq | APG279 (zumilokibart + APG990) | Atopic dermatitis | H2 2026 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList